OXISTAT (oxiconazole nitrate) by Sandoz is clinical pharmacology pharmacokinetics: the penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. First approved in 1988.
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
OXISTAT (oxiconazole nitrate) is a topical imidazole antifungal cream approved in 1988 for treating fungal skin infections including tinea pedis, tinea cruris, tinea corporis, and tinea versicolor. It works by inhibiting ergosterol biosynthesis in fungal cell membranes, disrupting cellular integrity. The drug demonstrates low systemic absorption with less than 0.3% recovered in urine, making it suitable for localized dermatological use.
OXISTAT is in LOE-approaching lifecycle with minimal Part D spending ($251K) and only 276 claims in 2023, indicating a mature, declining brand with a small, stable team focused on maintenance rather than growth.
CLINICAL PHARMACOLOGY Pharmacokinetics: The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm of oxiconazole nitrate cream onto human skin, the concentration of…
Worked on OXISTAT at Sandoz? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on OXISTAT offers limited career growth due to declining market position and LOE approaching status. Roles focus primarily on sales execution, generic competition management, and margin protection rather than innovation or market expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo